Aptose Reports Results for the First Quarter 2021
May 04, 2021 16:01 ET
|
Aptose Biosciences, Inc.
- Conference call and webcast at 4:30 pm EDT today - - Luxeptinib Phase 1 a/b studies in AML and B cell malignancies continue dose escalation - - APTO-253 Phase 1 a/b study in AML / MDS advances to...
Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021
April 26, 2021 16:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
April 08, 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Fourth Quarter and Full Year 2020
March 23, 2021 16:01 ET
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5pm EDT today - - Company announces resignation of CFO Gregory Chow - - Luxeptinib (CG-806) continues dose escalation and evidence of clinical activity - SAN DIEGO...
Aptose Expands Senior Leadership Team
March 16, 2021 07:30 ET
|
Aptose Biosciences, Inc.
George Melko, Pharm.D. joins as Vice President, Regulatory Affairs Robert Killion, Ph.D. appointed Vice President, CMC SAN DIEGO and TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Aptose...
Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021
March 02, 2021 16:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Presents Highlights from ASH and Corporate Update Event
December 06, 2020 17:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December...
Aptose to Hold Corporate Update Sunday, December 6th
December 01, 2020 07:30 ET
|
Aptose Biosciences, Inc.
Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers Poster Presentations for CG-806 and APTO-253 are scheduled for December 5th and 6th at 2020 ASH Annual Meeting...
Aptose Reports Results for the Third Quarter 2020
November 10, 2020 16:01 ET
|
Aptose Biosciences, Inc.
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level Nodal Reductions Observed and Dosing Continues in CG-806 Phase 1 a/b Study in CLL Patients Dosing Continues in...
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
November 04, 2020 10:17 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...